1. Home
  2. MDCX vs RNXT Comparison

MDCX vs RNXT Comparison

Compare MDCX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDCX
  • RNXT
  • Stock Information
  • Founded
  • MDCX 2008
  • RNXT 2012
  • Country
  • MDCX Canada
  • RNXT United States
  • Employees
  • MDCX N/A
  • RNXT N/A
  • Industry
  • MDCX
  • RNXT Biotechnology: Pharmaceutical Preparations
  • Sector
  • MDCX
  • RNXT Health Care
  • Exchange
  • MDCX Nasdaq
  • RNXT Nasdaq
  • Market Cap
  • MDCX 33.8M
  • RNXT 31.6M
  • IPO Year
  • MDCX N/A
  • RNXT 2021
  • Fundamental
  • Price
  • MDCX $2.97
  • RNXT $1.16
  • Analyst Decision
  • MDCX Strong Buy
  • RNXT Strong Buy
  • Analyst Count
  • MDCX 1
  • RNXT 1
  • Target Price
  • MDCX $10.00
  • RNXT $9.00
  • AVG Volume (30 Days)
  • MDCX 10.9K
  • RNXT 203.6K
  • Earning Date
  • MDCX 01-01-0001
  • RNXT 03-31-2025
  • Dividend Yield
  • MDCX N/A
  • RNXT N/A
  • EPS Growth
  • MDCX N/A
  • RNXT N/A
  • EPS
  • MDCX N/A
  • RNXT N/A
  • Revenue
  • MDCX N/A
  • RNXT N/A
  • Revenue This Year
  • MDCX N/A
  • RNXT N/A
  • Revenue Next Year
  • MDCX N/A
  • RNXT N/A
  • P/E Ratio
  • MDCX N/A
  • RNXT N/A
  • Revenue Growth
  • MDCX N/A
  • RNXT N/A
  • 52 Week Low
  • MDCX $1.80
  • RNXT $0.77
  • 52 Week High
  • MDCX $3.23
  • RNXT $1.86
  • Technical
  • Relative Strength Index (RSI)
  • MDCX N/A
  • RNXT 38.10
  • Support Level
  • MDCX N/A
  • RNXT $1.32
  • Resistance Level
  • MDCX N/A
  • RNXT $1.40
  • Average True Range (ATR)
  • MDCX 0.00
  • RNXT 0.09
  • MACD
  • MDCX 0.00
  • RNXT -0.03
  • Stochastic Oscillator
  • MDCX 0.00
  • RNXT 17.07

About MDCX Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Share on Social Networks: